CAJ | 학술논문

收集197例接受利奈唑胺治疗住院患者的临床资料,分析利奈唑胺所致Hb减少的情况及相关危险因素.利奈唑胺所致Hb减少的发生率为31.98％;Hb减少的患者与未减少的患者相比较年龄较大[(68±14)与(59±18)岁,P=0.000]、肌酐清除率(CCr)较低[(72±42)与(98±52) ml/min,P=0.000];多因素logistic回归分析结果显示,利奈唑胺相关Hb减少的危险因素包括年龄≥65岁、用药疗程≥15 d、CCr＜ 65 ml/min和基础Hb值＜95 g/L.
수집197례접수리내서알치료주원환자적림상자료,분석리내서알소치Hb감소적정황급상관위험인소.리내서알소치Hb감소적발생솔위31.98％;Hb감소적환자여미감소적환자상비교년령교대[(68±14)여(59±18)세,P=0.000]、기항청제솔(CCr)교저[(72±42)여(98±52) ml/min,P=0.000];다인소logistic회귀분석결과현시,리내서알상관Hb감소적위험인소포괄년령≥65세、용약료정≥15 d、CCr＜ 65 ml/min화기출Hb치＜95 g/L.
The medical records of 197 patients on linezolid therapy were collected retrospectively.The prevalence and risk factors for linezolid-induced reduction of hemoglobin were identified.The incidence of linezolid-induced reduction of hemoglobin was 31.98％.The patients with reduction of hemoglobin had older age [(68 ± 14) vs.(59 ± 18) years,P =0.000] and lower creatinine clearance (CCr) [(72 ±42)vs.(98 ± 52) ml/min,P =0.000].Multivariate logistic regression analysis showed that age ≥65 years,treatment duration ≥ 15 days,CCr ＜ 65 ml/min and pre-treatment hemoglobin value ＜ 95 g/L were significant risk factors for linezolid-induced reduction of hemoglobin.